ReviewNature reviews. Cardiology2025
Renal denervation for hypertension.
Review in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Article
- Patients' Experiences of Outcome Expectations in Renal Denervation: A Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Therapeutic approaches to hypertension: A selective perspective on emerging evidence.Journal of translational internal medicine · 2026Article
- Review
- Interventional strategies for pulmonary arterial hypertension: Current perspectives and future directions.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society.American journal of hypertension · 2026Review
- Unilateral Renal Denervation for Refractory Hypertension in Aortic Dissection.JACC. Case reports · 2026Article
- Renal denervation for successful pregnancy in a patient with chronic hypertension and history of preeclampsia: A case report.American journal of preventive cardiology · 2026Article
- Repositioning renal denervation in resistant hypertension: evidence-based insights, stratified decision-making, and implementation pathways.Frontiers in cardiovascular medicine · 2026Review
- Reframing renal denervation: from blood pressure reduction to autonomic disease modification-a state-of-the-art review.Clinical hypertension · 2026Review
- Effects of intrarenal afferent stimulation by bradykinin on renal sympathetic nerve activity: tonic inhibition contributing to renal function.Pflugers Archiv : European journal of physiology · 2025Article
- Cardiorenal Syndrome and Autonomic Overactivity.Biomedicines · 2025Review
- Ultra-stretchable, adhesive and photothermal multifunctional hydrogel for renal denervation to treat hypertension.Materials today. Bio · 2025Article
- Cryoablation for Renal Denervation: A Cool Alternative to Thermal Approaches?JACC. Basic to translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innovative therapies for hypertension are desperately needed given the rising prevalence and falling rates of control of hypertension despite an abundance of available medical therapies. Procedural interventions lower blood pressure without depending on adherence to medications, and endovascular renal denervation (RDN) is the interventional procedure with the best evidence base for the treatment of hypertension. After nearly two decades of study, with major refinements to devices, technique and trial design, two different systems for RDN received approval from the FDA in late 2023 for the treatment of hypertension. These decisions were based on a portfolio of sham-controlled clinical trials demonstrating efficacy and safety of both radiofrequency and ultrasound RDN in treating patients across the spectrum of hypertension, including patients with mild disease taking no or one medication as well as those with moderate and truly resistant hypertension. In this Review, we begin by summarizing the background and scope of the global problem of hypertension control and explore the evolution and mechanism of RDN. We then detail early studies and randomized clinical trials demonstrating the efficacy and safety of RDN procedures, review international statements, and provide practical guidance on patient selection and implementation of RDN, including the crucial aspects of building a hypertension team and of involving patients in shared decision-making.
Indexed as
Identifiers
39743561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.